M-032
- Generic Name
- M-032
- Drug Type
- Biotech
Study of Pembrolizumab and M032 (NSC 733972)
Phase 1
Recruiting
- Conditions
- Anaplastic AstrocytomaGliosarcomaGlioblastoma Multiforme
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 28
- Registration Number
- NCT05084430
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
Phase 1
Active, not recruiting
- Conditions
- Recurrent Glioblastoma MultiformeProgressive Glioblastoma MultiformeAnaplastic Astrocytoma or Gliosarcoma
- Interventions
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 29
- Registration Number
- NCT02062827
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath